

**Neuland Laboratories Limited** 

11th Floor (5th Office Level), Phoenix IVY Building, Plot No.573A-III, Road No.82, Jubilee Hills, Hyderabad - 500033, Telangana, India.

Tel: 040 67611600 / 67611700 Email: neuland@neulandlabs.com www.neulandlabs.com

June 10, 2024

To **BSE Limited** Phiroze Jeejeebhoy Towers, 25<sup>th</sup> Floor, Dalal Street, Mumbai - 400 001

The National Stock Exchange of India Ltd Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai - 400 001

Scrip Code: 524558 Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Madam,

Sub: Press Release - Change in the logo of the Company

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (" SEBI Listing Regulations"), we are enclosing herewith a Press Release dated June 10, 2024, titled "Neuland Unveils a Refreshed Brand Identity, marking a significant milestone in the company's evolution".

The new logo is unveiled as new corporate brand identity for internal as well as external stakeholders of the Company.

This is for your information and records.

Thanking you

Yours Sincerely, For Neuland Laboratories Limited

Sarada Bhamidipati Company Secretary

Encl: As above



## Neuland Unveils a Refreshed Brand Identity, marking a significant milestone in the company's evolution.

The dynamic new brand identity, reinforcing its commitment to agility, ethics, partnerships, and growth.

Hyderabad, India, June 10, 2024: Neuland Laboratories Limited (NLL) (NSE: NEULANDLAB; BSE: 524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services, today unveiled its new branding and visual identity marking a significant milestone in the company's evolution. The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress and reinforces its promise to agility, ethical practices, partnerships, and sustainable growth.



Built on the Company's strong legacy of 4 decades the logo reflects the values and ambition of the business. It serves as a visual embodiment of the organisation's shared values, acknowledging its history, whilst alluding to the promising future ahead. Neuland aims to be a reliable and trusted partner, delivering impactful solutions with a tenacious spirit that drives continuous improvement.

"In unveiling the new brand identity, Neuland remains committed to its mission of supporting its customers in advancing healthcare and improving patient outcomes. The Company invites stakeholders, partners, and the broader community to join us on this exciting journey toward a future where healthcare is synonymous with innovation, ethics, collaboration, and sustainable growth", said Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories

## **About Neuland Laboratories Limited**

For over 4 decades, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 100 APIs and has filed over 950+ Regulatory filings in the US (67 active US DMFs), the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID &GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

If you have any questions or require further information, please feel free to contact: <a href="Marketing@neulandlabs.com">Marketing@neulandlabs.com</a>.